Funding for this research was provided by:
Novartis Pharma, K.K., Tokyo, Japan
Article History
Received: 12 March 2020
Accepted: 23 October 2020
First Online: 9 January 2021
Compliance with Ethical Standards
:
: Y. Ogura, Consultant fee (Novartis, Bayer, Alcon, Wakamoto, HOYA, Astellas, Senju), Lecture fee (Santen, Kowa, Novartis, Bayer, Topcon, Nikon, Sanwa Kagaku Kenkyusho, Boehringer Ingelhein, Otsuka); R. Kawasaki, Consultant fee (Novartis, Bayer, Roche, Senju), Lecture fee (Novartis, Bayer, Senju, Astellas, Novo Nordisk, Santen, Kowa, Takeda, Pfizer, Topcon, Nitto Medic); M. Bauer, Employee (Novartis); V. Bezlyak, Employee (Novartis).
: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit.The data that support the findings of this study are available from JMDC Inc. but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of JMDC Inc.